Jasper Therapeutics (JSPR) : Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. 

• Sector: Healthcare
• Industry: Biotechnology
• Founded by Judith Shizuru and Susan Prohaska in March 2018 
• Headquartered in Redwood City, California
• Employees: 45
• https://jaspertx.com/

IPO Sept 27, 21: Redwood City-based Jasper Therapeutics debuted on Nasdaq Monday after it raised about $107 million in a merger with blank check company Amplitude Healthcare Acquisition Corp., much less than expected when they announced their deal earlier this year.

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported positive preliminary data from Jasper’s ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU. Substantial reductions in UAS7 were reported, with a mean change from baseline at 8 weeks of -26.6 in the 240mg single-dose cohort and multiple dosing regimens at or above 120mg demonstrating UAS7 changes of more than -25 points.